After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...

The U.S. private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving ...

| BioNTech is not planning further trials of its BNT111 vaccine candidate in the late-stage refractory melanoma setting, a ...

Boston Scientific shelled out $533 million to buy up the remaining equity it had in Nalu Medical, a private company that ...

Exelixis’ oral tyrosine kinase inhibitor (TKI) was tied to a 20% reduced risk of death from colorectal cancer, appearing to ...

Roche believes it has exited phase 3 with data to support talks with regulatory agencies, but the mixed results raise ...

Cancer treatment developer HistoSonics reeled in $250 million in an oversubscribed series D round of financing two months ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...

Leverage RWE strategically to build regulator-ready submissions.

Two European-based biotechs—Indivi of Switzerland and Clouds of Care of Belgium—have inked a collaboration deal with the goal of leveraging precision medicine tools to boost the early phase of ...

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...